Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from MorphoSys US Inc.

Illustrated Case Discussions: How Will You Leverage Recent Evidence in Relapsed/Refractory DLBCL Settings?

Release Date: September 3, 2020
Expiration Date: September 3, 2021

Activity Overview

Diffuse large B-cell lymphoma (DLBCL) is among the most common forms of non-Hodgkin lymphoma with an estimated 28,000 cases diagnosed in the United States each year. Historically, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been the standard of care for patients with DLBCL; and while R-CHOP is associated with an approximate 60% cure rate, 40% of patients are either refractory to R-CHOP or will relapse following treatment response. Accordingly, there is a growing armamentarium of treatments available for the management of relapsed/refractory DLBCL including anti-CD19 antibodies, CAR-T therapies, antibody-drug conjugates, and nuclear transport inhibitors. With expanding treatment options comes the challenge of determining best practices for patient care and making evidence-based treatment decisions.

This online, on-demand virtual symposium brings together renowned experts who manage and treat patients with DLBCL. In this educational program these experts will use a case-based format to discuss the latest data in regard to newly approved agents into the management of patients with relapsed/refractory DLBCL who are transplant-ineligible, as well as review emerging agents in the ever-expanding treatment landscape.

This educational activity is an archive of the live virtual symposium held on September 1, 2020.


Acknowledgment of Support

This activity is supported by an educational grant from MorphoSys US Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Assess current standards of care in the management of patients with DLBCL and unmet medical needs in therapy
  • Integrate evidence from landmark clinical trials among patients with relapsed/refractory in the context of clinical scenarios
  • Identify approaches to diagnose and manage treatment-related toxicities among patients with DLBCL
  • Discuss emerging therapies and ongoing clinical trials for patients with relapsed/refractory DLBCL

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Christopher R. Flowers, MD, MS, FASCO
Christopher R. Flowers, MD, MS, FASCO
Professor, Department Chairman (Lymphoma/Myeloma)
University of Texas D Anderson Cancer Center
Houston, Texas

Disclosures: Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, TG Therapeutics. Consultant: AbbVie, Bayer, Celgene (unpaid), Denovo Biopharma, Genentech/Roche (unpaid), Gilead, Karyopharm, OptumRx, Pharmacyclics/ Janssen, Spectrum.

Kami Maddocks, MD
Kami Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The James Cancer Hospital at The Ohio State University
Columbus, OH

Disclosures: Consultant: Celgene, Karyopharm, MorphoSys, Pharmacyclics.

Loretta J. Nastoupil, MD
Loretta J. Nastoupil, MD
Associate Professor
UT MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Celgene, Genentech, Janssen, Merck, TG Therapeutics. Consultant: Celgene, Genentech, Gilead, Janssen, Juno, Novartis, TG Therapeutics, Spectrum

Jason Westin, MD, MS, FACP
Jason Westin, MD, MS, FACP
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Curis, Forty Seven, Genentech, Janssen, Kite, Morphosys, Novartis, Unum. Consultant: AstraZeneca, Bristol Myers Squibb, Curis, Genentech, Janssen, Kite, MSPharma, Morphosys, Novartis.

Oreofe O. Odejide, MD, MPH
Oreofe O. Odejide, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Physician, Dana-Farber Cancer Institute
Boston, MA

Disclosures: Oreofe O. Odejide, MD, MPH has no relevant financial relationships with commercial interests.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By